Paradigm Capital Management Inc. NY Sells 133,400 Shares of OrthoPediatrics Corp. (NASDAQ:KIDS)

Paradigm Capital Management Inc. NY cut its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 93.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,000 shares of the company's stock after selling 133,400 shares during the quarter. Paradigm Capital Management Inc. NY's holdings in OrthoPediatrics were worth $232,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Invesco Ltd. boosted its position in shares of OrthoPediatrics by 3.0% during the fourth quarter. Invesco Ltd. now owns 16,363 shares of the company's stock valued at $379,000 after buying an additional 469 shares during the last quarter. Northern Trust Corp raised its stake in OrthoPediatrics by 0.3% during the 4th quarter. Northern Trust Corp now owns 193,798 shares of the company's stock valued at $4,492,000 after buying an additional 644 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of OrthoPediatrics by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,411 shares of the company's stock worth $612,000 after buying an additional 1,042 shares during the last quarter. R Squared Ltd purchased a new stake in OrthoPediatrics during the fourth quarter valued at $48,000. Finally, Bank of New York Mellon Corp boosted its position in OrthoPediatrics by 3.8% in the fourth quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company's stock worth $1,338,000 after purchasing an additional 2,099 shares during the last quarter. 69.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KIDS. Stifel Nicolaus cut their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, March 5th. Truist Financial lowered their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Lake Street Capital initiated coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a report on Thursday, May 8th. Finally, Piper Sandler lowered their price objective on OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.83.

Insider Transactions at OrthoPediatrics

In other news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $164,573.20. Following the completion of the sale, the chief executive officer now directly owns 319,155 shares of the company's stock, valued at $7,934,193.30. This trade represents a 2.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gregory A. Odle sold 5,359 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the sale, the insider now directly owns 148,788 shares of the company's stock, valued at $3,698,869.68. The trade was a 3.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 23,732 shares of company stock worth $589,978 in the last three months. Insiders own 32.70% of the company's stock.

OrthoPediatrics Price Performance

KIDS stock traded down $0.32 during mid-day trading on Friday, hitting $20.83. The company had a trading volume of 72,124 shares, compared to its average volume of 196,893. The company has a market capitalization of $505.90 million, a price-to-earnings ratio of -16.93 and a beta of 1.09. The company has a 50-day moving average price of $22.54 and a 200 day moving average price of $23.73. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19. OrthoPediatrics Corp. has a 12-month low of $20.25 and a 12-month high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The firm had revenue of $52.41 million during the quarter, compared to the consensus estimate of $51.68 million. On average, research analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.